We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
TPST-1120, a first-in-class, oral, selective PPARโบ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized...
Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in...
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.215 | 6.25 | 3.44 | 3.79 | 3.39 | 323830 | 3.60619608 | CS |
4 | -0.345 | -8.625 | 4 | 4.1799 | 3.0611 | 424403 | 3.49683001 | CS |
12 | -0.505 | -12.1394230769 | 4.16 | 6 | 3.03 | 934256 | 4.35978958 | CS |
26 | 0.555 | 17.9032258065 | 3.1 | 6 | 2.7606 | 1571320 | 3.8173109 | CS |
52 | 1.565 | 74.8803827751 | 2.09 | 9.77 | 0.17 | 3166796 | 5.86360486 | CS |
156 | -10.155 | -73.5336712527 | 13.81 | 41 | 0.17 | 1213115 | 6.3963656 | CS |
260 | -10.155 | -73.5336712527 | 13.81 | 41 | 0.17 | 1213115 | 6.3963656 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions